Arrowhead Research

Company Background

Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and infectious disease. Their platform technologies have yielded a range of targeted drug candidates under both internal and partnered development (1).  Arrowhead works with partners to create improved versions of traditional small molecule drugs (3).  Arrowhead is headquartered in Pasadena, CA and operates a 24,000 square foot research and development facility located in Madison, WI. Arrowhead's team consists of approximately 50 full time management and technical employees with expertise in technology development and commercialization (1).

Suppliers and Buyers

Arrowhead Research relies on third parties for various components and processes for their products. They try to have at least two sources for each component and process, but may not be able to achieve multiple sourcing because there may be no acceptable second source or the component or process sought may be so new that a second source does not exist (2).

Strategic Partnerships

Arrowhead Research actively seeks to have collaborations and licensing agreements with leading biopharmaceutical companies to advance the development and commercialization of their technology platforms and drug candidates. Partnerships provide access to external expertise and capital to complement their internal research and create commercialization opportunities in areas outside of the core focus areas (1).

artnerships with other pharmaceutical and biotech companies are the primary focus of Arrowhead’s business development efforts. Given the array of their siRNA delivery platforms, they expect to enter disease specific siRNA therapeutic collaborations and siRNA delivery collaborations with large pharmaceutical and biotechnology companies which they believe will provide the opportunity to generate revenue in the near term. Using Arrowhead’s experience, disease specific collaborations will seek to develop and optimize siRNA lead candidates based on disease targets supplied by the partners (2). 

Arrowhead Research has many subsidiaries and has partnerships through them as well. Through Unidym, a subsidiary of Arrowhead Research, Arrowhead has a partnership with NanoIntegris, Inc., an Illinois-based supplier of carbon nanotubes that went into effect on October 27, 2010 (4).

Innovation and Technology

The modular and synergistic design of each platform provides a broad base for the development of further products.  For example, Homing Peptides™ is a vast, proprietary library of peptides that have been shown to distinctly target nearly every tissue in the human body. This library is being mined for the development of peptide-drug conjugates.  Dynamic Polyconjugates™ is a small RNA delivery system that has been demonstrated to promote efficient knockdown and wide safety margins using a variety of siRNA molecules.  RONDEL™ is a clinical stage small RNA delivery system that has demonstrated several important "firsts to show" in RNA interference in human clinical trials, including: systemic siRNA delivery, dose dependent accumulation in target cells and RNAi mediated mRNA and protein knockdown (1).

Arrowhead is currently working on its hepatitis B virus (HBV) program which has completed all internal preclinical requirements and has named a clinical candidate. As such, the Company has initiated the final IND-enabling steps, including GMP manufacturing, GLP toxicology, and preparation of a pre-IND data package for the US FDA and foreign counterparts. The candidate, named ARC-520, is an RNAi therapeutic actively targeted to the liver using the company's Dynamic Polyconjugate (DPC) delivery system and includes two siRNA sequences targeting two different regions of the HBV genome.  The RNA sequences used in the clinical candidate were part of a large-scale screening program initiated by Roche prior to the acquisition by Arrowhead. The RNAs target regions highly conserved across the major HBV genotypes and ARC-520 contains two distinct RNAs as a strategy to minimize the potential development of resistance in individual patients. Consistent with the company's overarching strategy, the DPCs used in ARC-520 employ active ligand-mediated targeting specific to a receptor on hepatocytes. This approach results in high-potency knockdown of a target gene, validated in mice, rats, and non-human primates and it has demonstrated a low toxicity profile in primates enabling long term dosing (3).

Products (1)

  • Adipotide®: an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue.
  • ARC-520: an RNAi-based therapeutic that targets the hepatitis B virus for the treatment of chronic Hepatitis B.
  • CALAA-01: an RNAi-based therapeutic that targets solid tumors.

See the Arrowhead location page for more information.

Sources

  1. Arrowhead Research Corporation (2012). “About Us.” Retrieved on October 27, 2012 from www.arrowheadresearch.com/about
  2. 10K Form (2011, September 30).  “Arrowhead Research Corporation.” Retrieved on October 27, 2012 from www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091d10k.htm
  3. Nanotechnology Now (2012, June 6).  “Arrowhead Research Advances ARC-520 into IND-Enabling Studies for theTreatment of Hepatitis B and Provides Guidance on Development Timeline.” Retrieved on October 28, 2012 from www.nanotech-now.com/news.cgi?story_id=45308
  4. Arrowhead Research Corporation (2010, October 27). “Press Releases.” Retrieved on October 28, 2012 from www.arrowheadresearch.com/press-releases?page=3